id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_knprvzmplre5lark3gt55of23e	Bruce E. Johnson	MTP10-01: Impact of genomic changes on the treatment of lung cancer	2007	1	.pdf	application/pdf	1158	75	50	Impact of genomic changes on the treatment of lung cancer: MTP10-01 Impact of genomic changes on the treatment of lung cancer patients with lung cancer who had dramatic clinical responses to treatment with gefitinib. in cell culture experiments and in patients with lung cancer. Lung cancer cell lines with mutations of the Prospective studies of lung cancer patients with EGFR mutations Patients with EGFR mutations treated with gefitinib or RT) pulmonary toxicities associated with 5 completed trials of thoracic Late pulmonary toxicities occurred in 10-21% of patients. late lung toxicity was greater in trials with concurrent chemotherapy and radiotherapy had lower rates of late pulmonary toxicity (10%). Stereotactic body radiation therapy (SBRT) is being utilized with increasing frequency, especially for medically inoperable lung cancer patients. Gemcitabine pulmonary toxicity has been reported in 1-3% of patients gemcitabine has been tested in a phase II trial by Japan Lung Cancer 	./cache/work_knprvzmplre5lark3gt55of23e.pdf	./txt/work_knprvzmplre5lark3gt55of23e.txt